Aethlon Medical, Inc., a therapeutic technology company focused on unmet needs in global health and biodefense, announced that the United States Patent and Trademark Office has allowed US Patent Application Number 14/490,418 ("the '418 Application"), entitled "Method for removal of viruses from blood by lectin affinity hemodialysis." The allowed claims of the '418 Application embody cartridges for the Aethlon Hemopurifier, which removes viral particles from the blood or plasma of infected patients.  

The '418 Application is a continuation of US Patent Number 7,226,429, which embodies methods of reducing viral loads in the blood of individuals infected with a virus. Together, this intellectual property further protects the Aethlon Hemopurifier and secures Aethlon's position as a leader in pioneering therapeutic strategies to address viral infections.

The Aethlon Hemopurifier is a first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug Administration (FDA) has designated the Hemopurifier a "Breakthrough Device" related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier is a first-in-class therapeutic device designed to address life-threatening viral infections.  The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device related to the treatment of life-threatening viruses that are not addressed with approved therapies.

In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.  Based on its use to treat Ebola virus, the Hemopurifier was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.

Aethlon is also investigating the potential therapeutic use of the Hemopurifier to reduce the presence of tumour-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).